ClinicalTrials.gg
Status unknownNCT03501784Updated Mar 18, 2019

Nobio Antimicrobial Particles Effect in a Split Mouth Model

An interventional study of Nobio particles incorporated within Novidia Dental Bonding and Filtek bond and flow composite in Cervical Caries, sponsored by Nobio Ltd.. Status unknown at 1 site in Israel. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-18.

Sponsored by Nobio Ltd. · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study purpose is to evaluate the antimicrobial effect of Nobio particles incorporated within Novidia Dental Bonding and Flowable Composite versus standard of care within a split mouth model.The study population will include 35 subjects considered to be at high risk for cervical caries and affected by uncontrolled plaque accumulation

Read the detailed description

An exploratory, comparative, self-controlled single blinded interventional study. Intended to evaluate the antimicrobial effect of Nobio particles incorporated within Novidia Dental Bonding and Flowable composite versus Filtek bond and flow composite within a split mouth model.The study population (N=35) will be high risk population for cervical caries (with at least 2 carious cavities in the mouth) affected by uncontrolled plaque accumulation.Each subject will serve in this model as his own control.On one side the Novidia intervention will be made and on the contralateral side the Filtek intervention.

02

Conditions studied

  • Cervical Caries

Browse trials for

03

In context

Root Caries

39 studies on the registry are indexed under Root Caries; 14 are open to participants now.

This study's planned enrollment of 35 is below the median of 62 across 35 interventional studies indexed under Root Caries.

Browse Root Caries studies →

Lead sponsor

This is the only study on the registry with Nobio Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female over 18 years of age.
  • Requires two cervical restorations or the exchange of existing ones
  • Subject has poor oral hygiene and at high risk for plaque accumulation.
  • Subject able and willing to comply with study visits and Follow up visits and signed the .

Exclusion criteria

Exclusion Criteria:

  • Allergic reaction to iodide.
  • Pregnant or lactating women.
  • Use of antiseptic mouth rinse or antibiotic up to 2 weeks before the beginning of study.

Exclusion criteria for the chosen teeth for the study:

  • Tooth designated for extraction in the following 6 month.
  • Tooth designated to have a root canal treatment.
  • Tooth or several teeth designated for periodontal surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Novidia Dental bonding and flow

    Nobio particles incorporated within Novidia Dental Bonding and Flow.

    Device: Nobio particles incorporated within Novidia Dental Bonding

  • Active comparator
    Filtek bond and flow composite

    standard of care class V composite restoration performed with Filtek and 3M

    Device: Filtek bond and flow composite

Interventions

  • DeviceNobio particles incorporated within Novidia Dental Bonding

    Nobio particles incorporated within Novidia Dental Bonding and Flow

    Also known as: Device

  • DeviceFiltek bond and flow composite

    standard of care class V composite restoration performed with Filtek and 3M

06

What researchers measure

Primary outcomes

  1. Occurrence and severity of adverse events related to dental care

    Record unanticipated adverse device-related events (UADE),Incidence and nature of serious adverse events (SAE). Incidence and nature of adverse events

    Time frame: one year

Secondary outcomes

  1. Plaque index rate

    0 -No Plaque up to 3-Abundance plaque

    Time frame: one year

  2. Replica method for bacterial count

    Impression matrix sampling the tooth bio film layer

    Time frame: one year

  3. Physician assessment of cervical restoration integrity

    Marginal integrity of the performed restoration

    Time frame: one year

  4. Subject and Dentist satisfaction questionnaire

    satisfaction questionnaire ranging from 1(strongly disagree )to 10 (strongly agree)

    Time frame: one year

  5. Dead/Live Staining of biofilm (Cyto 9)

    CSLM quantitative measurement

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
  • Assuta Medical Center -Maccabident
    Tel Aviv, 5242321, Israel
    Recruiting
08

References and documents

Publications

  • Atar-Froyman L, Sharon A, Weiss EI, Houri-Haddad Y, Kesler-Shvero D, Domb AJ, Pilo R, Beyth N. Anti-biofilm properties of wound dressing incorporating nonrelease polycationic antimicrobials. Biomaterials. 2015 Apr;46:141-8. doi: 10.1016/j.biomaterials.2014.12.047. Epub 2015 Jan 28. PubMed 25678123 ↗
  • Beyth N, Yudovin-Farber I, Perez-Davidi M, Domb AJ, Weiss EI. Polyethyleneimine nanoparticles incorporated into resin composite cause cell death and trigger biofilm stress in vivo. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22038-43. doi: 10.1073/pnas.1010341107. Epub 2010 Dec 3. PubMed 21131569 ↗

Individual participant data

Plan to share: No — The final study results will be shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Sep 2019, 12 months after the start.

Of 21 interventional studies with no phase under Root Caries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
Apr 18, 2018
StartActual
Sep 22, 2018
Primary completionEst.
Sep 30, 2019
CompletionEst.
Dec 30, 2019
Last update
Mar 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03501784
Lead sponsor
Nobio Ltd.
Responsible party
Sponsor
First posted
Apr 18, 2018
Start date
Sep 22, 2018
Primary completion
Sep 30, 2019 (estimated)
Completion
Dec 30, 2019 (estimated)
Last update
Mar 18, 2019

Study contacts

Bertrude LEV DOR, DMD
Contact
levdor_b@maccabi-dent.com
972-54-772-0015
Bertrude LEV DOR, DMD
Contact
972-54-772-0015
Bertrude LEV DOR, DMD
principal investigator · MACCABIDENT ASSUTA
Bat sheva Levy
study director · Nobio Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion